Friday, 1 August 2014

OXFORD START UPS WIN GOOGLE'S PRIZE 500,000 Pounds / each


Two projects involving Oxford University technology are winners of 2014 Google Impact Challenge, and will each receive £500,000.


Life-changing ideas win Google Impact Challenge

Smart glasses for people with sight loss to make the most of their remaining vision – a partnership between the Royal National Institute of Blind People and a research team in the Nuffield Department of Clinical Neurosciences led by Dr Stephen Hicks, which won as the 'People's Choice' following a public vote.
Wearable acoustic sensors to track disease-carrying mosquitoes in Indonesia – a programme led by Royal Botanic Gardens Kew and Oxford's Department of Engineering Science, Malaria Atlas Project and the Eijkman Oxford Clinical Research Unit in Jakarta, which was selected by a panel of judges as one of this year's three other winners.





Passion for Persian Carpet: Kazem Mojtahedi,foremost connoisseur of Persian carpet offers his entire collection for sales on AUCTION, August 2nd August 3rd, August 4th, starting at noon, 

348 Davenport Road, Toronto ON M5R1K6  http://wp.me/p4PS6F-K

Saturday, 26 April 2014

Ontario Tax Exemption for Commercialization

digital technology
How to apply for a tax refund available to eligible start-ups that are commercializing intellectual property developed at Canadian universities and colleges.
Read More
http://www.ontario.ca/business-and-economy/ontario-tax-exemption-commercialization

Reza Moridi

Minister of Research and Innovation

The Ministry of Research and Innovation supports world-class research, commercialization and innovation taking place across Ontario through a range of programs and services like the Ontario Research Fund, Innovation Demonstration Fund and Ontario Venture Capital Fund.

The real impact of venture capital on Canadian businesses


Data released by CVCA - Canada's Venture Capital & Private Equity Association shows a 31% increase in venture capital investments in 2013, with total venture capital financing reaching a six-year high of $2 billion.
This SlideShare showcases results for the Canadian venture capital industry during 2013 as well as the real impact venture capital has had on Canadian businesses.http://www.bdc.ca/EN/solutions/venture_capital/newsroom/Pages/impact_vc_on_businesses.aspx

Monday, 14 April 2014

John R. Evans Leaders Fund - National Announcement

John R. Evans Leaders Fund - National Announcement - Canada News Centre







...As Canada's population ages, the number of Canadians
living with dementia is projected to double within a generation, thereby
affecting 1.1 million people and costing Canada's health care system in
excess of $150 billion.


It is therefore the kind of research our government is proud to sponsor.


Today, I am happy to announce that our government is investing in the state-of-the-art equipment necessary to build Dr. Heisz's Neurophysiology of Fitness Lab.


I am also pleased to announce that our government is investing more than $30.4 million in state-of-the-art equipment and infrastructure at 32 universities across Canada.



 Read More....



Speaking Points


The Honourable Ed Holder, PC, MP
Minister of State (Science and Technology)


Hamilton, Ontario


April 14, 2014

Sunday, 16 February 2014

Monitoring the state of food


Professor Lord John Krebs Kt FRS
Professor of Zoology & Principal of Jesus College Oxford
Baron John Krebs is the head of the UK's Food Standards Agency (FSA), between 2005 and 2008 he was the Royal Society Research Professor at Oxford.

In 2007 he chaired a working party of the Nuffield Council on Bioethics to produce a report on the Ethics of Public Health. He sits in the House of Lords as an independent cross-bencher and is Chairman of the House of Lords Science and Technology Select Committee.
He is also a Trustee of the Nuffield Foundation, Chairman of the UK Science and Technology Honours Committee.   He sits on the UK Climate Change Committee and chair its Adaptation Sub-Committee.  In 2012-3 I was President of the British Science Association.

His research interests lie in quantitative and experimental behavioural ecology and population biology, especially of bird populations.
He is a cross-bencher in the House of Lords and the Chairman of the House of Lords Science and Technology Select Committee. In 2007, he chaired a working party of the Nuffield Council on Bioethics to produce a report on the Ethics of Public Health. He is a Trustee of the Nuffield Foundation and Chairman of the UK Science and Technology Honours Committee. He sits on the UK Climate Change Committee and chairs its Adaptation Sub-Committee.
John Krebs was the first chairman of the UK Food Standards Agency from 2000 to 2005 and has a strong interest in all aspects of food policy.
His book, "Food, a very short introduction" (working title) will be published by Oxford University Press in 2013.
Website
http://www.zoo.ox.ac.uk/staff/academics/krebs%20of%20wytham_jr.htm

Monday, 27 January 2014

Google buys UK artificial intelligence start-up DeepMind

Google has bought UK start-up DeepMind for a reported $400m (£242m), making the artificial intelligence firm its largest European acquisition so far.
DeepMind was founded by 37-year-old neuroscientist and former teenage chess prodigy Demis Hassabis, along with Shane Legg and Mustafa Suleyman.
The artificial intelligence company specialises in algorithms and machine learning for e-commerce and games.
Technology news website Re/code first reported the purchase price.
But Google declined to confirm the figure, while privately-held DeepMind was not immediately available for comment.

Read More......


Saturday, 7 December 2013

Seedrs Appoints World-Class Advisory Board



Earlier this month, we announced our newly-appointed Advisory Board made up of four world-class individuals. We’re thrilled to welcome to the Seedrs family: 
  • James Alexander, co-founder of Zopa and partner at The Foundation. 
  • Mike Butcher, European Editor of TechCrunch.
  • Lord Lucas, Member of the House of Lords and Chief Editor of The Good Schools Guide. 
  • Dale Murray, British Angel Investor of the Year 2011, Non-Executive Director of UK Government’s Department of Business, Innovation & Skills (BIS) and of UK Trade and Investment (UKTI). 
  •  
  • Read their bios here..........

Monday, 25 November 2013

MinION™ device: a miniaturised sensing system



Nanopore sensing technology can be miniaturised into a portable device for electronic single molecule sensing. This is possible because of recent advances made by Oxford Nanopore in using new polymers to form robust, long lasting bilayers on its proprietary arrayed sensing chip.
The MinION™  system is a disposable device that contains the sensor chip, ASIC and nanopores that are needed to perform a complete single molecule sensing experiment. Plugging directly into a laptop or desktop computer through a USB port, it is a self-contained device to deliver real-time experimental data.
The MinION device is adaptable for DNA sequencing, protein sensing and other nanopore sensing techniques.
Workflows are similar to those of the GridION system. The system can run with Oxford Nanopore bioinformatic solutions or the user's own analysis systems in real-time, as the experiment is being performed.
Oxford Nanopore is focused on delivering the simplest possible sample preparation and workflows. The system is designed to be compatible with complex samples such as blood or serum and environmental samples such as water samples

Read More.....

Saturday, 16 November 2013

Oxbridge to Invest Up to $1 Billion in Medical Commercial Developments in US, Canada & Internationally

Oxbridge to Invest Up to $1 Billion in Medically Anchored Mixed Use Commercial Developments in the United States, Canada and Internationally



LONDON, UNITED KINGDOM and VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug. 19, 2013) - Oxbridge Capital today announced that it would invest up to $ 1 billion over the next 60 months in developing healthcare anchored mixed use commercial real estate developments in the United States, Canada and internationally. See www.oxbridgeventures.com.
According to investment guidance made public today, Oxbridge will develop these substantial real estate capital plays alongside a number of key strategic partners, including:
  • Integrated healthcare service providers, including companies providing a full range of physiotherapy, surgical, pharmaceutical, senior care and other services;

  • Hospital groups and integrated healthcare delivery systems;

  • REITs, including those involved in all aspects of mixed use commercial development, acquisition, finance and management;

  • Private equity real estate investment funds;

  • Investment management, infrastructure and other specialized funds;

  • Insurance companies;

  • Design build consortia, including large and well known construction and facilities maintenance operators in Canada, the United States, Europe and Asia; and

  • Various real estate development and structured finance professions in Toronto, New York, London and Singapore.

In structuring these investments, Oxbridge will leverage up to $250 million in internally generated and/or externally sourced funds and leverage the same with a combination of conventional bank debt, bond issuances, high yield financing, tax exempt offerings, structured finance and additional equity and debt offerings in the public and private markets. Oxbridge expects to announce its first set of transactions, including related financings approaching $500mm, within the next 12 to 18 weeks. The Company is already in advanced discussions on a number of potential projects in the United States, Canada and elsewhere.
Owners and operators of healthcare facilities and or development sites seeking to access these investment funds are encouraged to submit a brief business profile to krajani@oxbridgeventures.com.
About Oxbridge Capital Group
Oxbridge Capital is a private equity group that acts as financial sponsor for transactions in a number of key sectors, including real estate, transportation and logistics, hospitality, healthcare and energy and power. The principals at Oxbridge, its financing partners and related entities, have played an instrumental role in negotiating, structuring, and/or placing more than $20 billion in debt and equity securities over the past 20 years. See www.oxbridgeventures.com.

Gene Therapy Start up



Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases.
Our founding team has led the advancement of gene therapy research for nearly two decades, building a recognized center of gene therapy innovation in research, translation and manufacturing at The Children’s Hospital of Philadelphia Center for Cellular and Molecular Therapeutics (CCMT).
Spark Therapeutics is the next phase of our founders’ commitment. We are building a fully-integrated gene therapy company to realize the vision of delivering multiple products to address debilitating diseases. With a $50 million commitment from The Children’s Hospital of Philadelphia and exclusive technology agreements with multiple academic institutions, we have the capabilities needed to advance our clinical programs and deliver innovative medicines for those in need. Many of the CCMT’s leaders will assume management roles within Spark or engage with the company as scientific advisors, including Katherine A. High, M.D., a gene therapy pioneer who has served as the director of the CCMT since its inception.
Our team’s experience in the clinical study of gene therapy—from designing and manufacturing vectors to conducting studies that have shown strong potential for safety and efficacy—is unparalleled in the field. Clinical-grade vectors prepared by our team have been used to safely treat more than 100 human subjects in 12 clinical trials in the U.S. and EU, across five parenteral routes of administration in genetic and non-genetic diseases. No other group can claim this breadth of expertise and experience in human gene therapy.
The adeno-associated virus (AAV) vectors used in our clinical programs have been demonstrated to be safe and effective vehicles for delivering genetic material into targeted cells, providing unique advantages over alternative therapeutic approaches. We have established human proof of concept in two organ systems—the eye and the liver—and are advancing a Phase 3 program in blindness caused by mutations of the RPE65 gene; a Phase 1/2 program in hemophilia B; and preclinical programs in neurodegenerative diseases and other hematologic disorders and forms of inherited blindness.
 http://www.sparktx.com/about-spark

Sunday, 3 November 2013

IRISS EyE Check Device for Non-Specialists

Eye Health Informatics

iPad Displaying Eye Check StatisticsThe IRISS device captures in real-time crucial data relating to the eyes: pupil sizes, cornea diameter, palpebral aperture and so on. This data is aggregated on a Cloud-based platform where normative values are established. This in turn shows the clinician, in real time, a range of values for every eye-feature and assists them in making clinical decisions with regard to potential underlying conditions such as anisocoria, ptosis, buphthalmos and others.

The American Association of Paediatrics, the American Association of Paediatric Ophthalmology and Strabismus as well as the UK National Screening Committee and similar bodies around the world recommend that children undergo vision screening at least by the age of 4-5. The problem lies in the fact that while it is very desirable to detect these conditions even in babies and infants, this pre-verbal (often uncooperative) population, is very difficult to screen and diagnose accurately and reliably. This is the reason why many cases of amblyopia and strabismus are detected at the age of 6 or more, when it is almost too late for effective treatment. Hence there is a need for reliable and practical automatic screening and diagnostic technologies for these conditions.

Request Quotation: Consultant@oxfaz.org


The IRISS Eye Check provides a quick, easy and cost-effective method of screening for the condition that will both reduce over- and under-referrals and complement current examination techniques.
http://www.jaapos.org/article/S1091-8531(12)00462-4/fulltext

Tuesday, 22 October 2013

Society of Vacuum Coaters


Motion Control and Automation Technology NASA


Motion Control and Automation Technology
Anti-Icing Formulas Prevent Train Delays
In the winter of 2009, Washington, DC workers faced the prospect of a difficult commute due to record-setting snowfall. But thousands of the city's Metrorail riders found the public transportation system fully functional, thanks in part to a NASA technology invented years before. Just like trains...
Spacesuit Simulator Meets NASA Training Needs
Aurora Flight Sciences delivered a completed Space Suit Simulator (S3) to NASA following the successful completion of a Phase II Small Business Innovation Research (SBIR) effort. The S3 was developed to meet NASA's research and training needs. Pressurized spacesuits impose high joint torques on the astronaut, reducing mobility for upper and lower body motions. Because of the highly altered mobility...
  BRIEFS
A Short-Range Distance Sensor with Exceptional Linearity
A sensor has been demonstrated that can measure distance over a total range of about 300 microns to an accuracy of about 0.1 nm (resolution of about 0.01 nm). This represents an exceptionally large dynamic range of...
Miniature Trace Gas Detector Based on Microfabricated Optical Resonators
While a variety of techniques exist to monitor trace gases, methods relying on absorption of laser light are the most commonly used in terrestrial applications. Cavity-enhanced absorption techniques typically use...
Non-Magnetic, Tough, Corrosion- and Wear-Resistant Knives From Bulk Metallic Glasses and Composites
Quality knives are typically fabricated from high-strength steel alloys. Depending on the application, there are different requirements for mechanical and physical properties that cause problems for steel alloys..

Sunday, 13 October 2013

SME Smart IP Scheme (SSIPS)


ISIS Innovation
Two new initiatives were launched to make it even more attractive for clients to engage with Isis. An easy-to-use Materials Evaluation Agreement was launched by Isis, Imperial Innovations and UCL Business, to help companies evaluate new materials from the research laboratories of these three universities. Isis also launched its SME Smart IP Scheme (SSIPS) which offers greater flexibility and reduced business risk for SMEs accessing Intellectual Property (IP) from Oxford University. SSIPS ensures that, whatever the ultimate route to market, the SME that invested in the development will earn a share of future revenues. Furthermore, Isis works with SSIPS partners to access support initiatives such as TSB Smart Awards and R&D tax credits. 

Crowdfunding


http://youtu.be/qqOHD9mpoeI
http://www.learningcrowdfunding.com/our-products

Wednesday, 2 October 2013

Oral Drug Delivery Carrier


Oral Drug Delivery Carrier - Isis Project No 710155

Technology Source: Keele University

An oral, enteric drug delivery vehicle targeting PepT1 for increased bioavailability.
At the heart of this invention is a new approach to oral drug delivery. This is via a drug carrier system targeting the protein PepT1, allowing the oral administration of drugs that would otherwise need to be given by injection.

Unmet need

The market for improving oral bioavailability of drugs was estimated at $20B in 2010, highlighting it as a major issue for large and small biopharmaceutical companies that are looking to add high value to existing compounds. About 50% of new drugs with the desired biological activity fail to reach the market because of poor oral bioavailability, transport problems, or metabolism by the liver. For many drugs, the absorption is so low as to be ineffective, leading to further problems such as:
  • The bulk of the expensive drug (e.g. 90%) is wasted, so 10 times as much drug must be administered to achieve the desired medicinal effect
  • Drugs with low absorption usually show highly variable absorption between patients – e.g. 10% average absorption might have a 3-fold range either side of this value, with some patients absorbing 3% (limited benefit) and others 30% (potential side-effects)
This delivery system might thus provide a reliable protocol for achieving high oral bioavailability, which would overcome all of the problems outlined above.

The technology

Work on the bioavailability mechanisms led the researchers to explore the binding/transport of a thiodipeptide, which was found to be much more stable than normal peptides, but which was rapidly transported by PepT1. This was modified to create a 'carrier' molecule to which drugs could be attached. Although the primary focus is on the design of a drug carrier system, the expertise of the inventors also enables them to design small modifications to drugs that might allow them to be absorbed via PepT1 without compromising their biological efficacy. A number of drug conjugates have been tested in vivo, using single dose oral administration to rats, and monitoring blood plasma levels of the conjugate. The results show that the conjugates are orally absorbed in vivo, and this approach should have wide-ranging applicability.

Status and next steps

The team, comprising Prof. Patrick Bailey and others at Keele University, are keen to out-license this invention to a party that has capabilities to apply it across targeted therapy areas. The invention has been patented in several
major jurisdictions internationally.

Research group

Patrick Bailey is Professor of Chemistry and Dean of Faculty of Natural Sciences at Keele University. His research has focused on protein mechanisms, most recently on peptide transporters, and on synthesis of alkaloids with valuable pharmaceutical properties.

Request further information....

Thursday, 26 September 2013

Social Mobility: the greatest challenge of our time?





Education Endowment Foundation 



Sir Peter Lampl is Chair of the Education Endowment Foundation and the Sutton Trust.

The Sutton Trust-EEF Teaching and Learning Toolkit is an accessible summary of educational research which provides guidance for teachers and schools on how to use their resources to improve the attainment of disadvantaged pupils.

The Toolkit currently covers 33 topics, each summarised in terms of their average impact on attainment, the strength of the evidence supporting them and their cost.
The Toolkit is a live resource which will be updated on a regular basis as findings from EEF-funded projects and other high-quality research become available. In addition, we would welcome suggestions for topics to be included in future editions. If you have a topic suggestion, or any other comments or questions about the Toolkit, please contact Robbie Coleman at robbie.coleman@eefoundation.org.uk.


http://educationendowmentfoundation.org.uk/toolkit/

Saturday, 21 September 2013

Oxford Entrepreneurs

 
 Please submit your interest below if you had like to participate to be contacted.
john_stringfellow@oxfordentrepreneurs.co.uk
Please submit your interest below if you’d like to participate and someone will follow up shortly:
Please submit your interest below if you’d like to participate and someone will follow up shortly:
Please submit your interest below if you’d like to participate and someone will follow up shortly:
Please submit your interest below if you’d like to participate and someone will follow up shortly:
Mentor – Email: john.stringfellow@oxfordentrepreneurs.co

Cutting Edge Technology: Meet Lisa at Oxford

Begbroke Science Park RoboticsMeet Lisa. This is the latest big thing in the world of autonomously driven vehicles. Being currently developed by Prof. Paul Newman (Department of Engineering) and his research team at Begbroke Science Park, Lisa can be used in a variety of civilian and defence applications.
To read more click here.  

Laser Therapy for tissue generation





Toronto-based Theralase Inc. has collaborated with Ontario Centres of Excellence (OCE) and the University Health Network (UHN) for over a decade to develop its industry leading line of Low Level Laser Therapy products used in hospitals and medical clinics across North America.
Designed to treat wounds, increase tissue regeneration and reduce inflammation and pain, Theralase is the creator of one of only three FDA NHN (non-heating) approved therapeutic medical lasers licensed in the US and the only therapeutic laser system approved for chronic knee pain.
Read More...............
http://www.theralase.com/www/

Friday, 13 September 2013

OXFORD BUSINESS ALUMNI NETWORK

                                                                               

Social Media Groups

If you are using social media, you can apply to join the OBA Network Facebook and LinkedIn groups. Connect with business alumni and friends online, add to your social networks and find out about the latest alumni and School news. You can also join the relevant LinkedIn group just for your class, if you are an Oxford Alumnus, which will be listed on the drop down menu.
Please select a social media group below.
       GET CONNECTED